Starting a Mobile Drug-Testing Business

Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated August 2026

Quick answer: Mobile drug-testing franchises serve employers who lack collection infrastructure — the business is logistics and certification more than laboratory science.

Regulatory skeleton

Collections follow DOT 49 CFR Part 40 procedures whenever DOT-covered employees are involved: collector qualification training, error-correction competency, breath-alcohol technician certification for alcohol testing. State phlebotomy rules occasionally apply to blood draws (most mobile operators stick to urine/oral/hair).

Revenue mechanics

Typical economics: $35–$75 per mobile collection call, volume contracts with staffing agencies and trucking fleets, plus random-pool administration fees. National franchises (e.g., mobile-screening brands) sell territory models around these margins.

Certified labs nationwide · Results in 1–2 days

Need a test? Order online, test same-day →
Medical disclaimer: DrugPanels provides educational information about laboratory drug testing and does not offer medical advice, diagnosis, or treatment. Detection windows are population ranges — individual results vary with metabolism, dose, frequency and health status. Never stop prescribed medication to pass a test without talking to your prescriber. Affiliate disclosure: some links on this page are affiliate links; if you order through them we may earn a commission at no additional cost to you.

People also ask

Do prescriptions count against me?

No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.

Sources & further reading

  • SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
  • DOT — 49 CFR Part 40 procedures for transportation workplace testing
  • Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
  • FDA — drug-of-abuse test device labeling (detection window conventions)